Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

EMA committee adopts negative opinion on MAA for Kynamro in HoFH

Dec. 17, 2012

Roche presents novel hormone-sensitive lipase inhibitors

Dec. 17, 2012

FDA accepts NDA for Pfizer and Ligand's BZA/CE

Dec. 17, 2012

Japanese scientists present novel agents for Fabry's disease

Dec. 14, 2012

Lamazym advances to phase III alpha-mannosidosis trial

Dec. 14, 2012

Janssen submits NDA for canagliflozin/metformin combination

Dec. 14, 2012

Novel GR antagonists discovered to prevent antipsychotic-induced weight gain

Dec. 13, 2012

uniQure begins phase I study in acute intermittent porphyria

Dec. 13, 2012

PDC Biotech completes phase I trial of PDC-13 in primary dysmenorrhea

Dec. 13, 2012

Catabasis Pharmaceuticals synthesizes novel inhibitors of NF-kappaB signaling

Dec. 13, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...